Evidence map›Paper›PMID 30218864›Full record

Trial reportDrug and alcohol dependence2018

Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.

Erin A McClure, Nathaniel L Baker, Susan C Sonne, Udi E Ghitza, Rachel L Tomko, LaTrice Montgomery, Shanna Babalonis, Garth E Terry, Kevin M Gray

Open access · greenAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Drug and alcohol dependence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Erin A McClureDepartment of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States. Electronic address: mccluree@musc.edu.
Nathaniel L BakerDepartment of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.
Susan C SonneDepartment of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.
Udi E GhitzaCenter for Clinical Trials Network, National Institute on Drug Abuse, Bethesda, MD, United States.
Rachel L TomkoDepartment of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.
LaTrice MontgomeryAddiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Shanna BabalonisDepartment of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, United States.
Garth E TerryNorthwest Network Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, United States; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States.
Kevin M GrayDepartment of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.
Medical University of South Carolina · USNational Institute on Drug Abuse · USUniversity of Cincinnati Medical Center · USUniversity of Kentucky · USUniversity of Washington · US

Funding

Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
Southern Consortium Node of the Clinical Trials Network (Varenicline)UG1DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Kelly S. Barth · 2015 to 2026
$24.8M
Technological Innovations for the Remote Monitoring of Smoking in AdolescentsK01DA036739 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MCCLURE, ERIN A · 2014 to 2018
$771k
Twitter-Based Intervention for Young Adult African American Blunt SmokersK23DA042130 · NIDA · UNIVERSITY OF CINCINNATI · PI MONTGOMERY, LATRICE · 2017 to 2021
$726k
NIDA NIH HHS K01 DA036739NIDA NIH HHS K23 DA042130NIDA NIH HHS U10 DA013727NIDA NIH HHS UG1 DA013727
6 · The paper itself

Abstract

backgroundIt is common for cannabis users to also use tobacco. While data suggest that tobacco users have more difficulty achieving cannabis cessation, secondary analyses of clinical trial data sets may provide insight into the moderating variables contributing to this relationship, as well as changes in tobacco use during cannabis treatment. Those were the aims of this secondary analysis.

methodsThe parent study was a multi-site trial of N-acetylcysteine for cannabis dependence conducted within the National Drug Abuse Treatment Clinical Trials Network. Participants were treatment-seeking adults (ages 18-50) who met criteria for cannabis dependence (N = 302). For cigarette smokers (n = 117), tobacco use was assessed via timeline follow-back and nicotine dependence was assessed via the Fagerström Test for Nicotine Dependence (FTND). Outcome measures included: 1) changes in tobacco use based on treatment assignment, nicotine dependence, and concurrent cannabis reduction/abstinence, and 2) independent associations between nicotine dependence and cannabis abstinence.

resultsCigarette smokers accounted for 39% of the sample (117/302), with a median FTND score of 3.0 (10-point scale). Among those with lower baseline nicotine dependence scores, cigarette smoking was reduced in the active treatment group compared to placebo. Those with moderate/high levels of nicotine dependence showed slight increases in smoking following active treatment. Nicotine dependence did not affect cannabis cessation.

conclusionsCigarette smoking during cannabis treatment was affected, but depended on baseline nicotine dependence severity, though dependence levels did not impact cannabis abstinence. Interventions that address both tobacco and cannabis are needed, especially due to an increasing prevalence of cannabis use.

Indexed as

AcetylcysteineAdolescentAdultCigarette SmokingFemaleHumansMaleMarijuana AbuseMedical MarijuanaMiddle AgedSmoking CessationTobacco UseTobacco Use DisorderYoung AdultAcetylcysteineMedical MarijuanaCannabisCo-useMarijuanaN-acetylcysteinePharmacotherapyTobacco

Identifiers

PMID30218864
PMCPMC6200636
OpenAlexW2888027611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.